



WMB LETTER

E: 627042

Date: March 28, 2022

TO: support@tanasi.com – David B. Laroche
GreenWay Herbal Products, LLC (d/b/a Tanasi)
509 W. College Street
Murfreesboro, TN 37130

RE: Unapproved and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)

This is to advise you that the United States Food and Drug Administration (FDA) and the Federal Trade Commission

Some examples of the claims on your website and social media website that establish the intended use of your products and misleadingly represent them as safe and/or effective for the treatment or prevention of COVID-19 include:

- **“Do CBD Do Anything?”** . . .

At the University Of Chicago, a team led by Marsha Rosner discovered that CBD curbs COVID-19

work against several Covid variants.” . . .

CaCO: HCF 55

After announcing his new findings, van Breemen also said that cannabinoids ‘have the potential to prevent as well as treat infection by SARS-CoV-2.’ [from the January 14, 2022 blog post on your webpage <https://tanasi.com/blog/cannabis-and-covid-how-cannabinoids-could-prevent-infection/>]

- “

- **“The Hemp** . . .

The Medical College of Georgia and Dental College of Georgia recently conducted a relevant study. It showed that CBD could help reduce cytokine storms . . . and unrestricted lung inflammation in patients with Covid-19.” [from the November 17, 2020 blog post on your webpage <https://tanasi.com/blog/effects-of-hemp-on-inflammation/>]

- **“MDM**

Dexamethasone has recently emerged as the best drug to treat severe life-threatening cases of Coronavirus Disease 2019 (COVID-19). . . . Dexamethasone is a synthetic corticosteroid that is used as an anti-inflammatory or immunosuppressant agent. . . .

- **“WebHempCB** . . .

GreenWay Tanasi, LLC, and its brand, Tanasi, a subsidiary of GreenWay Herbal Products, LLC, sells a number of cannabidiol (CBD) products that feature a unique. P.1 .4 (/bl4.8 [(19))0.6 (.)6 (i)]TJ 0 Tc (-p/

FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and that are being misleadingly represented as safe and/or effective for the treatment or prevention of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the FD&C Act. This list can be found at

<http://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-covid-19-products>.

Once you have taken actions to address the sale of your unapproved and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.

This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.

If you are not located in the United States, please note that products that appear to be misbranded or unapproved new drugs may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products referenced above to be unapproved and misbranded products that cannot be legally sold to consumers in the United States.